Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-007 for prevention of vascular access graft failure
NCT00249002Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Nov 2005
- Primary completion
- Nov 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in vascular access graft dysfunction, sponsored by Celgene Corporation. Primary endpoints: Percentage of Participants With Discontinued, Delayed or Interrupted Therapy, Percentage of Participants Without Graft Failure or Need for Intervention at 24 weeks and 2 more. Started Nov 2005; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
vascular access graft dysfunction
Beyond the preview
Go deeper on NCT00249002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249002.